249 related articles for article (PubMed ID: 16234528)
1. Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies.
Ascierto PA; Scala S; Castello G; Daponte A; Simeone E; Ottaiano A; Beneduce G; De Rosa V; Izzo F; Melucci MT; Ensor CM; Prestayko AW; Holtsberg FW; Bomalaski JS; Clark MA; Savaraj N; Feun LG; Logan TF
J Clin Oncol; 2005 Oct; 23(30):7660-8. PubMed ID: 16234528
[TBL] [Abstract][Full Text] [Related]
2. Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo.
Ensor CM; Holtsberg FW; Bomalaski JS; Clark MA
Cancer Res; 2002 Oct; 62(19):5443-50. PubMed ID: 12359751
[TBL] [Abstract][Full Text] [Related]
3. Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: results from phase I/II studies.
Izzo F; Marra P; Beneduce G; Castello G; Vallone P; De Rosa V; Cremona F; Ensor CM; Holtsberg FW; Bomalaski JS; Clark MA; Ng C; Curley SA
J Clin Oncol; 2004 May; 22(10):1815-22. PubMed ID: 15143074
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of pegylated arginine deiminase for nonresectable and metastatic hepatocellular carcinoma.
Glazer ES; Piccirillo M; Albino V; Di Giacomo R; Palaia R; Mastro AA; Beneduce G; Castello G; De Rosa V; Petrillo A; Ascierto PA; Curley SA; Izzo F
J Clin Oncol; 2010 May; 28(13):2220-6. PubMed ID: 20351325
[TBL] [Abstract][Full Text] [Related]
5. Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma.
Ott PA; Carvajal RD; Pandit-Taskar N; Jungbluth AA; Hoffman EW; Wu BW; Bomalaski JS; Venhaus R; Pan L; Old LJ; Pavlick AC; Wolchok JD
Invest New Drugs; 2013 Apr; 31(2):425-34. PubMed ID: 22864522
[TBL] [Abstract][Full Text] [Related]
6. Drug evaluation: ADI-PEG-20--a PEGylated arginine deiminase for arginine-auxotrophic cancers.
Shen LJ; Shen WC
Curr Opin Mol Ther; 2006 Jun; 8(3):240-8. PubMed ID: 16774044
[TBL] [Abstract][Full Text] [Related]
7. Regression of hepatocellular cancer in a patient treated with arginine deiminase.
Curley SA; Bomalaski JS; Ensor CM; Holtsberg FW; Clark MA
Hepatogastroenterology; 2003; 50(53):1214-6. PubMed ID: 14571701
[TBL] [Abstract][Full Text] [Related]
8. Arginine deiminase, a potential anti-tumor drug.
Ni Y; Schwaneberg U; Sun ZH
Cancer Lett; 2008 Mar; 261(1):1-11. PubMed ID: 18179862
[TBL] [Abstract][Full Text] [Related]
9. A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma.
Mita MM; Rowinsky EK; Forero L; Eckhart SG; Izbicka E; Weiss GR; Beeram M; Mita AC; de Bono JS; Tolcher AW; Hammond LA; Simmons P; Berg K; Takimoto C; Patnaik A
Cancer Chemother Pharmacol; 2007 Feb; 59(2):165-74. PubMed ID: 16736151
[TBL] [Abstract][Full Text] [Related]
10. Pegylated arginine deiminase lowers hepatitis C viral titers and inhibits nitric oxide synthesis.
Izzo F; Montella M; Orlando AP; Nasti G; Beneduce G; Castello G; Cremona F; Ensor CM; Holtzberg FW; Bomalaski JS; Clark MA; Curley SA; Orlando R; Scordino F; Korba BE
J Gastroenterol Hepatol; 2007 Jan; 22(1):86-91. PubMed ID: 17201887
[TBL] [Abstract][Full Text] [Related]
11. Phase 1 study of weekly polyethylene glycol-camptothecin in patients with advanced solid tumors and lymphomas.
Posey JA; Saif MW; Carlisle R; Goetz A; Rizzo J; Stevenson S; Rudoltz MS; Kwiatek J; Simmons P; Rowinsky EK; Takimoto CH; Tolcher AW
Clin Cancer Res; 2005 Nov; 11(21):7866-71. PubMed ID: 16278410
[TBL] [Abstract][Full Text] [Related]
12. A phase-I study evaluating the combination of pegylated liposomal doxorubicin and paclitaxel as salvage chemotherapy in metastatic breast cancer previously treated with anthracycline.
Hong RL; Lin CH; Chao TY; Kao WY; Wang CH; Hsieh RK; Hwang WS
Cancer Chemother Pharmacol; 2008 Apr; 61(5):847-53. PubMed ID: 17609947
[TBL] [Abstract][Full Text] [Related]
13. Engineering an arginine catabolizing bioconjugate: Biochemical and pharmacological characterization of PEGylated derivatives of arginine deiminase from Mycoplasma arthritidis.
Wang M; Basu A; Palm T; Hua J; Youngster S; Hwang L; Liu HC; Li X; Peng P; Zhang Y; Zhao H; Zhang Z; Longley C; Mehlig M; Borowski V; Sai P; Viswanathan M; Jang E; Petti G; Liu S; Yang K; Filpula D
Bioconjug Chem; 2006; 17(6):1447-59. PubMed ID: 17105223
[TBL] [Abstract][Full Text] [Related]
14. Phase 1 clinical study of pegylated liposomal doxorubicin (JNS002) in Japanese patients with solid tumors.
Fujisaka Y; Horiike A; Shimizu T; Yamamoto N; Yamada Y; Tamura T
Jpn J Clin Oncol; 2006 Dec; 36(12):768-74. PubMed ID: 17095524
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma.
Thompson JA; Curti BD; Redman BG; Bhatia S; Weber JS; Agarwala SS; Sievers EL; Hughes SD; DeVries TA; Hausman DF
J Clin Oncol; 2008 Apr; 26(12):2034-9. PubMed ID: 18347008
[TBL] [Abstract][Full Text] [Related]
16. Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial.
Daud AI; Dawson J; DeConti RC; Bicaku E; Marchion D; Bastien S; Hausheer FA; Lush R; Neuger A; Sullivan DM; Munster PN
Clin Cancer Res; 2009 Apr; 15(7):2479-87. PubMed ID: 19318485
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of dacarbazine and thalidomide for the treatment of metastatic melanoma.
Ott PA; Chang JL; Oratz R; Jones A; Farrell K; Muggia F; Pavlick AC
Chemotherapy; 2009; 55(4):221-7. PubMed ID: 19451711
[TBL] [Abstract][Full Text] [Related]
18. A phase II trial of arsenic trioxide in patients with metastatic melanoma.
Kim KB; Bedikian AY; Camacho LH; Papadopoulos NE; McCullough C
Cancer; 2005 Oct; 104(8):1687-92. PubMed ID: 16130126
[TBL] [Abstract][Full Text] [Related]
19. A pilot study with vincristine sulfate liposome infusion in patients with metastatic melanoma.
Bedikian AY; Papadopoulos NE; Kim KB; Vardeleon A; Smith T; Lu B; Deitcher SR
Melanoma Res; 2008 Dec; 18(6):400-4. PubMed ID: 19011511
[TBL] [Abstract][Full Text] [Related]
20. Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group.
Chen CI; Kouroukis CT; White D; Voralia M; Stadtmauer E; Stewart AK; Wright JJ; Powers J; Walsh W; Eisenhauer E;
J Clin Oncol; 2007 Apr; 25(12):1570-5. PubMed ID: 17353550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
